Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05382650
Other study ID # PRO00028137
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 22, 2023
Est. completion date July 2024

Study information

Verified date August 2023
Source The Methodist Hospital Research Institute
Contact Michael Sirimaturos, PharmD
Phone 346-356-1685
Email mwsirimaturos@houstonmethodist.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational study will be conducted across the Houston Methodist system, including all hospital-based and freestanding emergency departments (ED), and up to 4 additional sites in the United States. The safety of human rabies immune globulin (HRIG) 300 IU/mL product (HyperRAB®) in pediatric patients has not been fully established. The purpose of this study is to evaluate the safety of HRIG 300 IU/mL when given to pediatric patients per standard of care for rabies postexposure prophylaxis (PEP) in the ED.


Description:

BACKGROUND: Rabies PEP consists of thorough wound cleansing, administration of HRIG 20 IU/kg body weight, and 4 to 5 doses of rabies vaccine. The safety of HRIG 300 IU/mL has been confirmed only for adult patients. Although the safety of HRIG 300 IU/mL in the pediatric population has not been fully established, there is no age limit on the FDA approved indication for HRIG 300 IU/mL, and it is routinely administered to pediatric patients as standard of care in the United States. STUDY DESIGN: This observational, multicenter, prospective study will collect information on safety events that occur up to 30 days after standard of care administration of HRIG 300 IU/mL among pediatric patients (age ≤17 years) at up to 5 study sites in the United States. Safety data will be collected using surveys and chart review of the health record. All participants will receive HRIG 300 IU/mL per standard of care prior to joining this study. The day of HRIG 300 IU/mL administration will be defined as day 0. The study will conduct Survey 1 on day 2 and Survey 2 on day 10 to collect information on adverse events (AEs). Investigators will review the electronic health record on day 30 to collect additional information on AEs. If a serious adverse event is detected during Survey 1, Survey 2, or the 30-day chart review and is not previously documented as being resolved or stabilized the study will conduct Survey 3 on day 30.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date July 2024
Est. primary completion date June 2024
Accepts healthy volunteers
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria 1. Received HRIG 300 IU/mL for rabies PEP during an ED encounter visit 2. Aged =17 years Exclusion Criteria 1. HRIG 300 IU/mL dose given is <18 IU/kg or >22 IU/kg 2. Patient is admitted or transferred to a hospital from the ED for further management of injuries related to the animal exposure 3. Patient has a history of rabies vaccine or rabies immune globulin administration 4. Legally authorized representative (parent) does not speak English if patient is <7 years old 5. Legally authorized representative (parent) or patient does not speak English if patient is 7 to 17 years old 6. Inability to obtain consent 1. More than 3 days passed since HRIG 300 IU/mL administration prior to screen 2. Unable to contact legally authorized representative (parent) and/or patient within 3 days of HRIG 300 IU/mL administration 3. Legally authorized representative (parent) and/or patient declined participation 7. Administration sites for HRIG are unknown

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Human rabies immune globulin 300 IU/mL
All participants in this single-cohort observational study will receive human rabies immune globulin 300 IU/mL at a dose of 20 IU/kg per standard of care.

Locations

Country Name City State
United States Houston Methodist Houston Texas
United States Texas Children's Hospital Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
The Methodist Hospital Research Institute Grifols Biologicals, LLC

Country where clinical trial is conducted

United States, 

References & Publications (3)

Hanna K, Cruz MC, Mondou E, Corsi E, Vandeberg P. Safety and neutralizing rabies antibody in healthy subjects given a single dose of rabies immune globulin caprylate/chromatography purified. Clin Pharmacol. 2018 Jun 26;10:79-88. doi: 10.2147/CPAA.S166454. eCollection 2018. — View Citation

Hwang GS, Rizk E, Bui LN, Iso T, Sartain EI, Tran AT, Swan JT. Adherence to guideline recommendations for human rabies immune globulin patient selection, dosing, timing, and anatomical site of administration in rabies postexposure prophylaxis. Hum Vaccin Immunother. 2020;16(1):51-60. doi: 10.1080/21645515.2019.1632680. Epub 2019 Aug 1. — View Citation

Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, Meltzer MI, Dhankhar P, Vaidya SA, Jenkins SR, Sun B, Hull HF; Advisory Committee on Immunization Practices Centers for Disease Control and Prevention (CDC). Human rabies prevention--United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2008 May 23;57(RR-3):1-28. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of local and systemic adverse events (AEs) within 2 days of HRIG 300 IU/mL administration Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration Within 2 days of HRIG 300 IU/mL administration
Secondary Cumulative incidence of all local and systemic AEs within 10 days of HRIG 300 IU/mL administration Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration Within 10 days of HRIG 300 IU/mL administration
Secondary Cumulative incidence of all local and systemic AEs within 30 days of HRIG 300 IU/mL administration Proportion of patients with 1 or more AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration Within 30 days of HRIG 300 IU/mL administration
Secondary Cumulative incidence of all local and systemic serious adverse events (SAEs) within 30 days of HRIG 300 IU/mL administration Proportion of patients with 1 or more SAE deemed as possibly/definitely related to HRIG 300 IU/mL administration. An AE is considered "serious" if any of the following outcomes occur:
Death
Life-threatening AE (life-threatening in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)
In-patient hospitalization or prolongation of existing hospitalization
A persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
An important medical event (refers to events which may not be immediately life-threatening, or result in death, or hospitalization, but from medical and scientific judgment, may jeopardize the participant or/and may require medical or surgical intervention to prevent one of the other outcomes listed above).
Within 30 days of HRIG 300 IU/mL administration
Secondary Type and severity of individual local and systemic AEs detected within 30 days of HRIG 300 IU/mL administration Proportions of AEs that are local vs systemic and proportions of AEs that are mild, moderate, or severe among AEs deemed as possibly/definitely related to HRIG 300 IU/mL administration Within 30 days of HRIG 300 IU/mL administration
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05975658 - WIReD: Wireless Interstage Remote Device Study
Completed NCT03921346 - Reducing Prehospital Medication Errors & Time to Drug Delivery by EMS During Simulated Pediatric CPR N/A
Completed NCT04301206 - Videos and Simple Text to Empower Parents to Handle Their Sick Children N/A
Not yet recruiting NCT04087070 - Blood Pressure Estimation Using Noninvasive Biosignals During Pediatric Anesthesia
Recruiting NCT06273228 - Parenting Young Children in Pediatrics N/A
Recruiting NCT05480930 - Improving Nighttime Access to Care and Treatment; Part 4-Haiti N/A
Not yet recruiting NCT05815563 - Validation of Peripheral Perfusion Index in Predicting Successful Supraclavicular Brachial Plexus Block in Pediatrics
Recruiting NCT02556541 - Ultrasound-guided Peripheral Vascular Access in Children N/A
Recruiting NCT02908113 - Visual Perception in Preterm Infants N/A
Not yet recruiting NCT01678066 - A Prospective Study to Bilaterally Compare a Non-Invasive Cardiac Output Monitor N/A
Completed NCT04993599 - Evaluation of Social Robot Usability for Pediatric Patients and Carers N/A
Completed NCT05537168 - Bayesian Networks in Pediatric Cardiac Surgery
Completed NCT01603628 - BOTOX® Treatment in Pediatric Lower Limb Spasticity Phase 3
Completed NCT01603615 - BOTOX® Open-Label Treatment in Pediatric Upper Limb Spasticity Phase 3
Completed NCT06098105 - Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block vs Laparoscopic Intraperitoneal Instillation of Local Anesthetic in Pediatrics N/A
Completed NCT01418846 - Determination of Voriconazole Levels in Saliva - Validation in Specific Subsets of Patients N/A
Completed NCT01460329 - Comparing Cardiac Output Measurements in Critically Ill Children Using USCOM and Transthoracic ECHO N/A
Withdrawn NCT00666393 - An Evaluation of Safety of the Fentanyl Transdermal System for Management of Acute Post-Operative Pain in Pediatric Patients Phase 3
Recruiting NCT03337581 - Pharmacodynamics and Pharmacokinetics of Dexmedetomidine in Pediatric Phase 4
Recruiting NCT05275881 - Impact of Virtual Reality in Pediatric Hematology and Oncology N/A